Siltuximab
Siltuximab Basic information
- Product Name:
- Siltuximab
- Synonyms:
-
- Siltuximab
- Research Grade Siltuximab(DHC15801)
- Siltuximab (anti-IL-6)
- CNTO-328
- Research Grade Siltuximab
- CAS:
- 541502-14-1
- MW:
- 0
- Mol File:
- Mol File
Siltuximab Chemical Properties
- storage temp.
- Store at -20°C
- form
- Liquid
- color
- Colorless to light yellow
Siltuximab Usage And Synthesis
Uses
Siltuximab it is used for cancer treatment using anti-ICOS antibody if patient has low peripheral T cell receptor clonality.
Clinical Use
Chimeric (human-murine) immunoglobulin G1κ
(IgG1κ) monoclonal antibody:
Treatment of multicentric Castleman’s disease
(MCD)
in vivo
Siltuximab (intraperitoneal injection; 10 mg/kg; 3 times per week) inhibits the growth of lung cancer cells in xenograft mouse model[1].
Siltuximab (intraperitoneal injection; 20 mg/kg; twice per week; 6 w) inhibits the growth of MCF-7 tumor in xenograft model[4].
| Animal Model: | Female CD-1 nu/nu mice injected with H1650 (adenocarcinoma), H322 (adenocarcinoma), or H157 (squamous) cells[1] |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection; 10 mg/kg; 3 times per week |
| Result: | Repressed PY-STAT3 levels stimulated by IL-6 in H322 cells. Repressed PY-STAT3 levels in H1650 cells. Inhibited the growth of tumors with H322 and CAF cells. Inhibited the growth of tumors with H1650 and CAF cells. |
| Animal Model: | Female NOD-SCID mice with MCF-7 tumor[4] |
| Dosage: | 20 mg/kg |
| Administration: | Intraperitoneal injection; 20 mg/kg; twice per week; 6 weeks |
| Result: | Blocked MCF-7 engraftment, induced regressions in 90% of tumors. |
Drug interactions
Potentially hazardous interactions with other drugs
Live vaccines: risk of generalised infections - avoid.
Ciclosporin and tacrolimus: monitor levels on
initiation and discontinuation of siltuximab as it may
reduce the activity of CYP450.
Metabolism
As siltuximab is a monoclonal antibody, the expected consequence of metabolism is proteolytic degradation to small peptides and individual amino acids, and receptormediated clearance.
SiltuximabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com